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Great saphenous vein diameter does not correlate
with worsening quality of life scores in patients
with great saphenous vein incompetence
Kathleen Gibson, MD,a Mark Meissner, MD,b and David Wright, MD,c Bellevue and Seattle, Wash; and
London, United Kingdom
Objective: Previous studies have correlated increasing great saphenous vein (GSV) diameter with increasing CEAP clinical
classification. Some insurance carriers are currently using specific GSV diameters to determine coverage for treatment of
axial venous insufficiency. The aim of this study was to investigate the correlation of patient quality of life (QOL)
measures with GSV diameters in varicose vein patients with GSV reflux.
Methods:Data were collected from the records of 91 patients prospectively enrolled in two varicose vein trials. The patients
had symptomatic varicose veins with saphenofemoral junction and proximal GSV reflux. Maximum GSV diameter was
measured on duplex ultrasound imaging, with the patient standing, within 5 cm of the saphenofemoral junction. Chronic
Venous Insufficiency Questionnaire 2 (CIVIQ-2; Servier, Neuilly-sur-Seine, France), Venous Insufficiency Epidemio-
logical and Economic Study (VEINES) Symptom (Sym) and QOL assessments, and the Venous Clinical Severity Score
(VCSS) assessment were completed before treatment of GSV insufficiency. Demographic information, patient weight,
height, and bodymass index were collected. Correlations between pairs of data were done using Pearson product-moment
and Spearman correlation coefficients.
Results: The 91 study patients (19 men, 72 women) were a mean age of 45 years (range, 18-65 years). The mean GSV
diameter was 6.7 mm (range, 2.2-14.1 mm). The mean VCSS score was 7.8 (range, 3-12). There was a weak correlation
between increasing GSV diameter and VCSS (r  0.23; P  .03) and no correlation between GSV diameter and the
CIVIQ-2 score (r  0.01), VEINES-QOL (r  0.07), and VEINES-Sym (r  0.1).
Conclusions: GSV diameter is a poor surrogate marker for assessing the effect of varicose veins on a patient’s QOL; thus,
using GSV diameter as a sole criterion for determining medical necessity for the treatment of GSV reflux is inappropriate.
Further correlations betweenQOLmeasures and duplex-derived objective findings are warranted. (J Vasc Surg 2012;56:
1634-41.)
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(Currently, several insurance carriers in the United
States have restricted coverage of venous ablation proce-
dures to patients in whom the saphenous vein diameter
reaches a specific duplex-derived size.1,2 These measure-
ments do not differ by patient sex, age, or body size. United
Healthcare, for example, requires that the diameters of the
great saphenous vein (GSV) and the small saphenous vein
(SSV) must each measure at least 5.5 mm to qualify for
coverage. The goal of these restrictions, presumably, is to
provide an objective measure to divide patients with a
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1634edical necessity for treatment of GSV reflux from those in
hom treatment is for cosmetic purposes or in whom the
ffect of varicose veins on their activities of daily living
ADLs) and quality of life (QOL) is not significant.
Previous studies have found that worsening CEAP
linical class correlates with increasing saphenous trunk
iameters.3-5 The Chronic Venous Insufficiency Question-
aire 2 (CIVIQ-2; Servier, Neuilly-sur-Seine, France)6 and
he Venous Insufficiency Epidemiologic and Economic
tudy (VEINES) Quality of Life/Symptom (QOL/Sym)
uestionnaires7 are venous-specific patient-derived assess-
ents that have been used as tools to assess baseline QOL
nd evaluate outcomes of clinical trials.8 These QOL in-
truments have been validated in multiple patient popula-
ions.6,7,9,10 The VEINES study group showed that in-
reasing CEAP clinical class was associated with decreasing
atient QOL.11 The validity of extrapolating data from
hese studies to use vein diameter as a surrogate marker for
ffect on QOL has not been established.
The primary objective of this study was to determine if
he diameter of the GSV correlates with patient-derived
ather than physician-derived measurements of disease se-
erity. Secondary objectives included correlation of patient
orphologic measurements (height, weight, and body
ass index [BMI]) with Venous Clinical Severity Scores
VCSS) and QOL scores, and correlation of QOL scores
ith each other and with the physician-derived VCSS.
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An Institutional Review Board approved the experi-
mental protocols of the trials reported in this study and
informed consent forms. All participants gave informed
consent.
Patients. The data for this study were obtained from
two clinical trials sponsored by BTG International Ltd
(London, UK). The purpose of the first trial was to com-
pare a proprietary polidocanol endovenous microfoam vs
placebo in the treatment of GSV or anterior accessory
saphenous vein (AASV) incompetence conducted at four
clinical sites in the United States.12 The second trial com-
pared QOL measurements, VCSS, and photography of the
affected limb in patients before and after treatment with
radiofreqency ablation (RFA) or endovenous laser treat-
ment (EVLT) of the GSV or the AASV. The data from the
second trial used in this study were from one clinical site
(the first author’s) because this was the only site that had
data available for GSV measurements. From both data sets,
we examined only the data from patients with GSV incom-
petence (excluding the patients with incompetence of the
AASV alone). Data were contributed by 75 individuals in
the first trial and by 16 in the second trial. GSV diameters
were available on all 91 patients, and reflux times were
available in 82 patients.
To be eligible for the trials, patients had to be between
the ages of 18 and 65 years, have symptomatic varicose
veins without active ulcers (CEAP clinical class C3–5 for the
first trial and C2–5 for the second trial), and have reflux
0.5 seconds at the saphenofemoral junction (SFJ) and
proximal GSV while standing. Exclusion criteria included
venous ulceration, arterial insufficiency, obesity preventing
compression of the treated limb, pregnancy, and breast-
feeding. Patients with concomitant deep venous insuffi-
ciency (with exception of deep venous insufficiency limited
to the segment of the common femoral vein adjacent to the
incompetent SFJ) were excluded from the two trials.
Data collected. GSV diameters and reflux times were
measured by registered vascular technologists with the
patient standing. The GSV diameter used was the widest
diameter of the GSV within 5 cm of the SFJ, measured to
0.1 mm. The reflux time was recorded in this same location
to 0.1 second after manual calf compression.
To qualify as a study site, each vascular laboratory
submitted a dossier of duplex scans and interpretations to
an outside reviewer for adequacy. After this review, GSV
diameters in each patient were collected one time at entry
into the study by a single prequalified registered vascular
technologist (intraobserver and interobserver variability
was not performed as part of the study). Each patient
completed the CIVIQ-2, VEINES-Sym, and VEINES-
QOL questionnaires, and physicians completed VCSS be-
fore treatment.
Statistical analysis. Patient demographics, morpho-
metric data, GSV diameter and reflux time data, VCSS
scores, and the QOL scores were collected in an Excel
database (Microsoft, Redmond, Wash) and underwent de- acriptive analysis. Distribution of QOL scores was normal-
zed to allow analysis between data pairs using Pearson
roduct-moment correlation coefficients (transforming the
cores to parametric data). Spearman correlation coeffi-
ients were also determined, and the results from this
nalysis were virtually identical to the evaluation using
earson correlation coefficients, with the exception of the
ata pairs of VCSS vs GSV diameter. For that data pair,
pearman correlation coefficients () were calculated, and
or the sample size of 91 pairs of data, correlations were
onsidered strong at a negative or positive r  0.5 to 1.0,
oderate at r  0.3 to 0.49, weak at r  0.1 to 0.29, and
bsent at r 0.1. Statistical significance of r was deter-
ined using a critical values table for the Pearson and
pearman correlation coefficients.
ESULTS
Demographic, morphometric, and GSV diameter char-
cteristics of the patient population are reported in Table I.
he population was fairly typical for patients with varicose
eins: 79% were women, and the mean age was 45 years.
ighty-seven of the patients were white, two were Asian,
ne was Hispanic, and one was African-American. There
as a wide range of heights, weights, and BMIs repre-
ented, ranging from patients who would be considered
nderweight (BMI, 18 kg/m2) to the grossly obese (BMI,
2 kg/m2). GSV diameters varied widely, from 2.2 to 14.1
m, with a mean diameter of 6.7 mm (standard deviation
SD], 2.4 mm). According to CEAP clinical class, six
atients (6.6%) were C2, 75 (82.4%) were C3, eight (8.8%)
ere C4, and two (2.2%) were C5. Reflux times were amean
f 5 seconds (SD, 2 seconds; range, 0.6-15 seconds). One
atient had a GSV with a reflux time of 1 second.
Table II summarizes the VCSS and QOL scores for the
atient population. The physician-derived VCSS was fairly
ow, with a mean score of 6.4, showing that this population
as relatively mild to moderate venous disease from a
hysician’s perspective. Pearson product-moment correla-
ion coefficient analysis was performed to assess the corre-
ation between the VCSS and the QOL measures (Table
II). A moderate, statistically significant correlation existed
etween the VCSS and the CIVIQ-2, VEINES-Sym, and
EINES-QOL scores. A strong correlation was present
able I. Patient characteristics
ariable No. or mean (range)
ex
Male 19
Female 72
ge, years 45 (18-65)
eight, cm 168 (135-203)
eight, kg 77.9 (48.6-114.3)
MI, kg/m2 27.4 (17.8-41.7)
SV diameter, mm 6.7 (2.2-14.1)
MI, Body mass index; GSV, great saphenous vein.mong the three QOL measures.
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time, VCSS, and QOLmeasurements are reported in Table
IV. This analysis showed a weak correlation between GSV
diameter and VCSS and a very weak and statistically insig-
nificant correlation between GSV diameter and VEINES-
Sym scores. No correlation existed between GSV diam-
eter, CIVIQ-2, and VEINES-QOL scores or between
reflux time, VCSS, and any of the QOL scores. The
analysis comparing GSV diameter to the physician-derived
and patient-derived measures is shown in Figs 1 to 4,
which show scatterplots of GSV diameter, VCSS, VEINES-
SYM, VEINES-QOL, and CIVIQ-2 scores with best-fit
lines.
Table V reports correlation analyses of patient height,
Table II. Venous Clinical Severity Score (VCSS) and
quality of life (QOL) scores
Assessment Mean (range)
VCSS 6.4 (3-12)
CIVIQ-2 42.5 (20-85)
VEINES
Symptoms 40.5 (12-60)
QOL 82.7 (35-118)
CIVIQ-2,Chronic Venous Insufficiency Questionnaire-2;VEINES,Venous
Insufficiency Epidemiological and Economic Study.
Table III. Pearson coefficient correlations (r values)
between Venous Clinical Severity Score (VCSS) and
quality of life (QOL) measures
Variable VCSS CIVIQ-2 VEINES-Sym VEINES-QOL
VCSS 1 0.43 0.37 0.44
CIVIQ-2 1 0.83 0.90
VEINES-Sym 1 0.96
VEINES-QOL 1
CIVIQ-2, Chronic Venous Insufficiency Questionnaire 2; Sym, symptoms;
VEINES, Venous Insufficiency Epidemiological and Economic Study.
P  .01 for all correlations.
Table IV. Correlations (r values) between great
saphenous vein (GSV) diameter and reflux time, and
assessments of disease and quality of life
Assessment
GSV
diameter
Reflux
time
(n  91) (n  82)
VCSSa 0.23b –0.05
CIVIQ-2c 0.01 0.01
VEINES-Symc 0.10 0.00
VEINES-QOLc 0.07 0.02
CIVIQ-2, Chronic Venous Insufficiency Questionnaire 2; VCSS, Venous
Clinical Severity Score; VEINES-Sym/QOL, Venous Insufficiency Epidemi-
ological and Economic Study-Symptoms/Quality of Life.
aSpearman correlation.
bP  .02, all other P values insignificant.
cPearson correlation.weight, and BMI with GSV diameter and reflux time. This analysis showed a weak but statistically significant correla-
ion between increasing weight and BMI with GSV diam-
ter but no correlation between patient height and GSV
iameter. There was a trend toward statistical significance
n a weak inverse correlation between height and reflux
ime, and BMI and reflux time.
ISCUSSION
A population-based study conducted by Kaplan et al13
n 2003 estimated that approximately 24% of adults have
aricose veins and that significant association exists between
isease severity and patient QOL. Extrapolating these data
o the current population of the United States,14 approxi-
ately 74 million adult Americans have varicose veins.
he prevalence and severity of superficial venous insuffi-
iency increases with age,13,15 and as the United States
opulation grows and ages, the number of patients with
aricose veins is expected to increase. Studies have shown
hat treatment of varicose veins not only improves pa-
ient QOL8 but is also more cost-effective than conser-
ative management.16 On the basis of a comprehensive
eview of current literature, clinical practice guidelines
ecently published by a joint committee of the Society for
ascular Surgery and the American Venous Forum have
ecommended endovenous thermal ablation (RFA or
VLT) over conservative management or open surgery
n symptomatic patients (CEAP C2) with GSV incom-
etence.17
Procedures performed in the United States to treat
ncompetence of the GSV have steadily increased since the
.S. Food and Drug Administration approved RFA in
999 and EVLT in 2002. The 153,000 RFA procedures,
11,000 EVLTs, and 16,000 vein strippings were per-
ormed in 2010. From 2007 to 2013, the number of
VLTs is projected to increase by 14.5%, RFA by 15.3%,
nd stripping will fall by 16%.18 Decreased postoperative
ain, avoidance of general anesthesia, and quicker return to
ormal activities offered by these new technologies have
ndisputablymade treatment of venous incompetencemore
ttractive to patients.19-22
Ablation procedures performed in the outpatient set-
ing are less expensive than vein stripping performed in the
ospital23,24; however, the increase in total venous proce-
ures being performed has certainly caught the attention of
nsurance payers. Although improvements in QOL, a de-
rease in days off from work and in disability in patients
reated for varicose veins are beneficial to society and cost-
ffective in the long-term, the increase in procedures in the
hort term is an unwelcome additional demand on health
nsurance companies.
Undoubtedly in response to the increase in ablation
rocedures, insurers have placed restrictions on the cov-
rage of treatment for varicose veins. Most insurance
arriers in our region require a trial of “conservative
anagement,” usually consisting of requiring patients to
ear compression stockings for a specified period of
eeks or months, and often requiring a chronic need for
nalgesics, and documentation on impact of ADLs, de-
(VCSS).
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agement is beneficial.17
More recently, insurance companies have begun plac-
ing restrictions on coverage of varicose vein treatment
based not solely on physicians’ determinations of medical
necessity and on patient-reported symptoms and effect on
ADLs but on specific duplex-derived measurements, in-
cluding vein diameters. Ostensibly, GSV diameter is being
used as a surrogate marker to indicate disease and to
differentiate patients with “medical necessity” for vein
treatment from those in whom the treatment is for cos-
metic reasons. The effect of venous insufficiency on patient
QOL lacks a readily definable objective surrogate marker
such as exists for arterial insufficiency (eg, walking dis-
tance). The ultimate goal of any venous therapy should be
to improve patient QOL, not to improve findings on
anatomic and hemodynamic assessments. The use of surro-
gatemarkers to define successful end points for vein therapy
has been criticized,15 and our results would argue that the
use of such markers to segregate patient populations into
groups that should or should not be covered for vein
treatment should be questioned as well.
The diameter of the GSV has never been used as a
criterion to define venous reflux.17,25 Authors studying the
use of GSV diameter as a marker for hemodynamic impair-
ment have hadmixed results. Navarro et al4 in 2002 studied
82 patients and concluded that a GSV diameter of 5.5
mm had a 78% specificity and a 87% sensitivity in predicting
absence of “pathologic reflux.” In 2008, Musli et al26
studied 182 patients and concluded that the sensitivity
(69.7%) and specificity (64.6%) of GSV diameter in
predicting “hemodynamically significant reflux” was
poor. GSV diameter can vary with patient positioning,
Valsalva maneuvers, and BMI.27 Although other authors
have shown a correlation between CEAP clinical class
and GSV diameter,3-5 CEAP clinical class and patient
QOL,28,29 and CEAP clinical class and VCSS,30 there
are no published data directly correlating GSV diameter
with patient QOL.
Our data show that in the described patient population,
GSV diameter has only a weak association with VCSS and
nonexistent correlation with patient QOL scores. QOL
scores have an excellent correlation with each other and a
Table V. Pearson coefficient correlations (r values)
between great saphenous vein (GSV) diameter, reflux
time, patient weight, height, and body mass index (BMI)
Variable
GSV
diameter Reflux time
(n  91) (n  82)
Weight 0.26a 0.04
Height 0.07 0.19b
BMI 0.25a 0.21b
aP  .02.
bP  .10.moderate correlation with VCSS. These data support the oecent publication by Shepherd et al,8 who investigated the
orrelation between venous disease-specific QOLmeasure-
ents with hemodynamic and anatomic assessments. The
OL assessment tools that they studied were the Aberdeen
aricose Vein Questionnaire (AVVQ) and the Specific
uality-of-life and Outcome Response Venous (SQOR-V)
uestionnaire. The authors concluded that the QOL mea-
ures correlated well with each other, had a weak but
tatistically significant correlation with VCSS, and poor
orrelation with anatomic reflux (Venous Segmental
isease Score and venous refill times).8 The Shepherd et
l data, as well as our findings, demonstrate that the
ssessment of the effect of superficial venous insuffi-
iency on patient QOL cannot be simply assessed with
urrogate anatomic or hemodynamic markers. Although
revious works do correlate increasing GSV diameter
ith increasing CEAP clinical class, this correlation does
ot extend to patient perceptions of the effect of their
enous disease on their life. As such, basing coverage for
ein treatment on something as simple as GSV diameter is at
est arbitrary.
QOL was measured in these patients many times dur-
ng their evaluation and treatment, but only once in the
untreated” state at the entry of study. The QOLmeasure-
ents at study entry were the only values used in this
eport. Multiple QOL measurements in the same patient
efore treatment would be more meaningful by adding
trength to our findings. We would argue, however, that
his study more closely mimics what happens in real clinical
ractice. The physician generally does not see the patient at
ultiple visits before recommending vein treatment. Pa-
ients are referred for evaluation, are seen, and then usually
ndergo a duplex evaluation. Multiple duplex evalua-
ions to validate GSV diameter and multiple visits or
atient contacts to assess the effect on QOL would be
mpractical and not reimbursed. The impetus for this report
as the policy of a number of payers to limit treatment of
SV insufficiency to patients in whom the GSV diameter
et a specific threshold. This report correlates a single
ssessment of GSV diameter with a patient-derived QOL
easurement at a single time point, as is done in clinical
ractice.
This study has several limitations. GSV diameter, as
easured by duplex scanning, can have interobserver
nd intraobserver variability and can also vary depending
n time of day, patient positioning, and room tempera-
ure. Every effort was made to standardize patient posi-
ioning, room temperature, and scanning technique for
SV measurements; however, the scan was performed
nly once for each patient, and the time of day was not
ontrolled.
Another limitation of this study is that this patient
opulation had predominantly mild to moderate clinical
enous insufficiency (CEAP clinical class C2-3 disease).
oth trials specifically excluded patients at CEAP C1 and
6 and one trial excluded C2 patients. As such, this cohort
ay not well characterize a typical practitioner’s population
f patients with varicose veins because patients with more
11
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under-represented. It is possible that there is an association
between GSV diameter and patient QOL in a patient
population with more severe clinical disease (CEAP C4–6).
Further investigation in a patient population more heavily
represented by patients with higher CEAP clinical classes is
warranted.
CONCLUSIONS
GSV diameter is a poor surrogate marker for assessing
the effect of varicose veins on a patient’s QOL; thus, it is
inappropriate to use GSV diameter as a sole criterion for
determining medical necessity for the treatment of GSV
reflux. Further correlations between QOL measures and
duplex-derived objective findings are warranted.
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